Plain-English translation of NCT06890494 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Read our Leukemia research guide →Phase 1 — Testing in a small group (usually 20–80 people) to find a safe dose and watch for side effects.
This is an early-stage clinical trial testing a new treatment called for adults with a type of blood cancer (acute B-cell leukemia) that has either returned after previous treatment or is no longer responding to standard therapies. Researchers want to learn whether the medication can help treat this serious condition and what side effects patients might experience. This is one of the first studies of this treatment in people.
Many patients with relapsed or hard-to-treat acute B-cell leukemia have limited options, especially those who cannot receive other advanced treatments like CAR-T cell therapy. This trial exists to explore whether this new medication could offer hope to patients who have run out of standard treatment choices.
You likely qualify if…
You likely don't qualify if…
If you join this trial, you would receive the medication every other day for 1 to 2 months and keep a diary of any symptoms you experience. After the treatment period, you would visit the clinic once every 4 weeks for checkups and blood tests to see how you are responding. The entire study period would involve regular monitoring to track both how well the treatment is working and any side effects that develop.
AI-generated summary from trial data · Jul 3, 2026 · Not medical advice
China